Novartis, Rhapsido, Remibrutinib, FDA Approval, Symptomatic Dermographism, SD, Chronic Spontaneous Urticaria, CSU, Chronic Inducible Urticaria, CIndU, BTK Inhibitor

BASEL, Switzerland — October 7, 2026 Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Rhapsido®...